These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19622578)

  • 1. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
    Cruz-Munoz W; Man S; Kerbel RS
    Clin Cancer Res; 2009 Aug; 15(15):4867-74. PubMed ID: 19622578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
    Cruz-Munoz W; Man S; Xu P; Kerbel RS
    Cancer Res; 2008 Jun; 68(12):4500-5. PubMed ID: 18559492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic chemotherapy in the treatment of malignant melanoma.
    Lens MB; Eisen TG
    Expert Opin Pharmacother; 2003 Dec; 4(12):2205-11. PubMed ID: 14640919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of malignant melanoma at the stage of distant metastasis].
    Garbe C; Eigentler TK
    Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
    Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
    Minor DR; Madland MT; Kashani-Sabet M; Denny SR; Harvey WB
    Cancer Biother Radiopharm; 2005 Oct; 20(5):479-86. PubMed ID: 16248763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
    Tsubaki M; Takeda T; Obata N; Kawashima K; Tabata M; Imano M; Satou T; Nishida S
    J Cell Physiol; 2019 Aug; 234(10):17975-17989. PubMed ID: 30834527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
    Nystrom ML; Steele JP; Shamash J; Neville F; Oliver RT
    Melanoma Res; 2003 Apr; 13(2):197-9. PubMed ID: 12690305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Eggermont AM; Kirkwood JM
    Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.